Get the Stockscreener App
224.49
0.32%
0.72
After Hours:
223.10
-1.39
-0.62%
Overview
News
Price History
Option Chain
Financials
Why DHR Down?
Discussions
Forecast
Stock Split
Dividend History
Danaher Corp stock is traded at $224.49, with a volume of 4.42M.
It is up +0.32% in the last 24 hours and up +3.94% over the past month.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
See More
Previous Close:
$223.77
Open:
$223.37
24h Volume:
4.42M
Relative Volume:
0.95
Market Cap:
$157.81B
Revenue:
$24.78B
Net Income/Loss:
$3.68B
P/E Ratio:
43.39
EPS:
5.1743
Net Cash Flow:
$5.29B
1W Performance:
+5.99%
1M Performance:
+3.94%
6M Performance:
+19.95%
1Y Performance:
+23.71%
1-Day Range:
$221.60
$224.90
1-Week Range:
$209.60
$226.65
52-Week Range:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Name
Danaher Corp
Sector
Industry
Phone
(202) 828-0850
Address
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
224.49 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
675.00 | 249.58B | 45.20B | 6.87B | 6.75B | 18.19 |
NTRA
Natera Inc
|
412.56 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.79 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
270.37 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-02-25 | Initiated | Morgan Stanley | Overweight |
| Oct-08-25 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-10-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Mar-14-25 | Upgrade | Stifel | Hold → Buy |
| Feb-03-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Dec-19-24 | Initiated | Guggenheim | Buy |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-31-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-18-23 | Initiated | HSBC Securities | Hold |
| Dec-13-23 | Resumed | Wolfe Research | Peer Perform |
| Dec-07-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-01-23 | Initiated | SVB Securities | Outperform |
| Apr-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-18-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Oct-24-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-17-22 | Resumed | Bernstein | Outperform |
| Jul-20-22 | Initiated | UBS | Buy |
| Jun-01-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-11-22 | Initiated | Bernstein | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-10-21 | Reiterated | BofA Securities | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Reiterated | Goldman | Buy |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Apr-07-21 | Resumed | Robert W. Baird | Outperform |
| Mar-03-21 | Resumed | Barclays | Overweight |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-25-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-16-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-02-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-26-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-03-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Resumed | Stifel | Hold |
| Oct-28-19 | Reiterated | Needham | Buy |
| Oct-14-19 | Resumed | Credit Suisse | Outperform |
| Jul-19-19 | Reiterated | Needham | Buy |
| Jun-11-19 | Initiated | Piper Jaffray | Neutral |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| Apr-17-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Reiterated | Needham | Buy |
| Feb-25-19 | Upgrade | Janney | Neutral → Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Apr-20-18 | Reiterated | Stifel | Buy |
View All
Danaher Corp Stock (DHR) Latest News
Danaher Corp Lobbyists, 2022 - OpenSecrets
Danaher Corp. stock slips before the bell - AD HOC NEWS
What Does Veralto's (NYSE:VLTO) Dividend and Climate Validation Signal? - Kalkine Media
Danaher Corporation stock sets October earnings date - AD HOC NEWS
Danaher stock heads into the open after a 2.43 percent gain - AD HOC NEWS
Danaher stock ends the day 2.43 percent higher at USD 221.09 - AD HOC NEWS
Danaher Corp. stock holds near USD 200 before October results - AD HOC NEWS
Danaher (DHR) Institutional Ownership 2026 $DHR - MarketBeat
Danaher stock rises 0.16 percent ahead of the open - AD HOC NEWS
Automated Microscopy Market Advances as AI-Powered Image Analysis Transforms Digital Pathology and Semiconductor Inspection - GlobeNewswire Inc.
Danaher stock rises 2.38 percent after the close - ad-hoc-news.de
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Danaher Schedules Third Quarter 2026 Earnings Conference Call - marketscreener.com
Danaher will webcast its next financial update Oct. 21 - Stock Titan
Danaher Corp. stock gains as valuation stays above fair value - AD HOC NEWS
Danaher Corp. stock gains 1.97 percent ahead of the open - AD HOC NEWS
Danaher stock ends the day 1.97 percent higher at the close - AD HOC NEWS
Danaher stock holds steady as reduced growth outlook tempers sentiment - AD HOC NEWS
Goldman Sachs Adjusts Price Target on Danaher to $250 From $210, Maintains Buy Rating - marketscreener.com
Danaher (DHR) Stock Forecast and Price Target 2026 $DHR - MarketBeat
Danaher stock heads into the open after a modest loss - AD HOC NEWS
Danaher Corp. stock gains after UBS starts coverage with USD 250 target - AD HOC NEWS
Danaher stock gains after UBS starts coverage at USD 250 - AD HOC NEWS
Why Is Danaher (DHR) Drawing Fresh Attention? - Kalkine Media
Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better - Yahoo Finance
DHR|Danaher Corp|Price:221.090|Chg%:+5.250 - TradingKey
A new gene-editing tool is designed to reduce off-target edits - Stock Titan
Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation - Yahoo Finance
Danaher Corp (DHR) Shares Surge 3.0% -- What GF Score of 80 Tells Investors - GuruFocus
Danaher Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Danaher Announces Quarterly Dividend - Yahoo Finance
Danaher Corp. stock holds near USD 200 as investors eye earnings and guidance - ad-hoc-news.de
Danaher Corp. stock underperforms Thursday when compared to competitors - MarketWatch
UBS assumes coverage on Danaher stock with buy rating, $250 target - Investing.com Nigeria
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says - Yahoo Finance
Danaher Corp. stock gains support from UBS buy rating and July earnings beat - ad-hoc-news.de
Danaher stock heads into the open after a 0.87 percent slip - ad-hoc-news.de
Danaher Corp. stock outperforms competitors despite losses on the day - MarketWatch
Danaher stock holds near $207 after Q2 beat - ad-hoc-news.de
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
Danaher stock heads into the open after a 0.5 percent dip - ad-hoc-news.de
Danaher Corp stock edges lower as investors weigh latest analyst targets and dividend signal - ad-hoc-news.de
Danaher (NYSE:DHR): Is Its Next Move Tied to Inflation Data? - Kalkine Media
Danaher stock holds after Q2 revenue and EPS beat - AD HOC NEWS
Danaher Corp. stock underperforms Friday when compared to competitors - MarketWatch
Danaher Corp. stock trades near 52-week highs as investors digest recent earnings - AD HOC NEWS
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Danaher (DHR) Seen Deftly Navigating AI Integration - Yahoo Finance
Baird Adjusts Price Target on Danaher to $238 From $232, Keeps Outperform Rating - marketscreener.com
Danaher (DHR) Stock Trades Near Fair Value But At An Earnings Premium - Yahoo Finance
Danaher Corp. stock holds steady after recent pullback as investors weigh Q2 2026 results - AD HOC NEWS
Danaher Corp Stock (DHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):